Background:To compare the quality of life outcome between nurse-led and non-nurse-led interventions for patients with cancer using a meta-analysis.Methods:A systematic literature review was performed by searching randomized controlled trials about nurse-led interventions in PubMed, EMBASE, and Cochrane Library databases until June 2017. Pooled summary estimates for quality of life outcome was calculated as standardized mean difference (SMD) either on a fixed- or random-effect model via Stata 13.0 software.Results:Seven literatures involving 1110 patients (554 in the nurse-led group and 556 in the control group) were included. Pooled analysis showed there were no differences in the global quality of life, cognitive, emotional, role, social and physical functions, appetite loss, diarrhea, and dyspnea scales of Quality of Life Questionnaire C30 version 3.0 core (QLQ-C30) questionnaires between the nurse-led and control groups. However, the nurse-led management program significantly decreased the occurrence of constipation (SMD = −0.36, 95% CI = −0.71 to −0.00; P = .001) and insomnia (SMD = –0.33, 95% CI = −0.99 to 0.32; P = .011) and reduced the financial difficulty (SMD = −0.34, 95% CI = −0.65 to −0.03; P = .033) for patients with cancer.Conclusion:The nurse-led disease management strategy seemed to be effective to improve constipation, insomnia, and financial impacts for patients with cancer in quality of life assessment.

<b><i>Introduction:</i></b> Prognostic nutritional index (PNI) was indicted as a potential prognostic biomarker for cancer. However, the conclusion remains uncertain for renal cell carcinoma (RCC). This study was to confirm the association of PNI with prognosis and clinicopathological features in RCCs. <b><i>Methods:</i></b> The PubMed, EMBASE, Cochrane Library, CNKI, and Wan Fang databases were searched to retrieve eligible studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled to assess the strength of the association. <b><i>Results:</i></b> Fifteen studies were included. The results showed a low pretreatment PNI level was significantly associated with poor overall survival (HR = 1.67, 95% CI: 1.45–1.92), progression-free survival (HR = 1.72, 95% CI: 1.23–2.42), cancer-specific survival (HR = 1.17, 95% CI: 1.09–1.26), disease-free survival (HR = 1.28, 95% CI: 1.09–1.26), and recurrence-free survival (HR = 2.14, 95% CI: 1.38–3.31). This prognostic role of PNI was almost not changed by subgroup analysis based on study design, HR source, RCC type, sample size, cutoff, follow-up, treatment, and country. Furthermore, low PNI was correlated with old age, large tumor size and high T stage, Fuhrman grade, lymph node, and distant metastases. <b><i>Conclusion:</i></b> Pretreatment PNI might be a promising indicator to beforehand predict the progression and prognosis for RCC patients.